Factive 320 - Abdi Ibrahim

In studies spanning 2004 to 2007, gemifloxacin demonstrated remarkable potency against resistant respiratory pathogens. Compared to older quinolones, it showed superior efficacy against quinolone-resistant strains of Mycoplasma and Ureaplasma. Against S. pneumoniae, gemifloxacin maintained complete susceptibility in all tested isolates, outshining alternatives like moxifloxacin and gatifloxacin, especially in strains with two or more QRDR mutations. It also exceeded critical resistance thresholds for fAUC/MIC ratios in wildtype S. pneumoniae, suggesting its potential to slow resistance development. Additionally, gemifloxacin's broad-spectrum activity against H. influenzae and M. catarrhalis further reinforces its utility in managing respiratory infections. These findings position gemifloxacin as a powerful option for treating AECB and other infections caused by resistant bacterial strains.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Factive 320 by Abdi Ibrahim, consult with your doctor or healthcare professional.